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Abstract 
Background: Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer-related deaths 
worldwide. Up to 80% of cancer patients are classified as non-small-cell lung cancer (NSCLC) and cisplatin remains as 
the gold standard chemotherapy treatment, despite its limited efficacy due to both intrinsic and acquired resistance. 
The CK2 is a Ser/Thr kinase overexpressed in various types of cancer, including lung cancer. CIGB-300 is an antitumor 
peptide with a novel mechanism of action, since it binds to CK2 substrates thus preventing the enzyme activity. The 
aim of this work was to analyze the effects of CIGB-300 treatment targeting CK2-dependent signaling pathways in 
NSCLC cell lines and whether it may help improve current chemotherapy treatment.
Methods: The human NSCLC cell lines NCI-H125 and NIH-A549 were used. Tumor spheroids were obtained through 
the hanging-drop method. A cisplatin resistant A549 cell line was obtained by chronic administration of cisplatin. Cell 
viability, apoptosis, immunoblotting, immunofluorescence and luciferase reporter assays were used to assess CIGB-
300 effects. A luminescent assay was used to monitor proteasome activity.
Results: We demonstrated that CIGB-300 induces an anti-proliferative response both in monolayer- and three-
dimensional NSCLC models, presenting rapid and complete peptide uptake. This effect was accompanied by the 
inhibition of the CK2-dependent canonical NF-κB pathway, evidenced by reduced RelA/p65 nuclear levels and NF-κB 
protein targets modulation in both lung cancer cell lines, as well as conditionally reduced NF-κB transcriptional 
activity. In addition, NF-κB modulation was associated with enhanced proteasome activity, possibly through its α7/
C8 subunit. Neither the peptide nor a classical CK2 inhibitor affected cytoplasmic β-CATENIN basal levels. Given that 
NF-κB activation has been linked to cisplatin-induced resistance, we explored whether CIGB-300 could bring addi-
tional therapeutic benefits to the standard cisplatin treatment. We established a resistant cell line that showed higher 
p65 nuclear levels after cisplatin treatment as compared with the parental cell line. Remarkably, the cisplatin-resistant 
cell line became more sensitive to CIGB-300 treatment.
Conclusions: Our data provide new insights into CIGB-300 mechanism of action and suggest clinical potential on 
current NSCLC therapy.
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Background
Protein kinases are critical components of signaling path-
ways as they can promote or repress gene expression 
through reversible phosphorylation of target proteins [1]. 
Altered levels or activity of kinases may have dramatic 
effects on the control of cell growth, proliferation and 
apoptosis resulting in a high variety of human diseases 
including cancer [2].
The protein kinase CK2, formerly known as casein 
kinase 2, phosphorylates serine or threonine residues 
within acidic domains regulating a wide range of cellu-
lar processes. CK2 is probably the most pleiotropic pro-
tein kinase known, with more than 300 substrates already 
identified [3]. Related to cancer biology, CK2 phosphoryl-
ates many transcription factors, proto-oncoproteins and 
tumor suppressor proteins. In fact, the over-expression 
of CK2 catalytic subunits exacerbates the tumor pheno-
type, consistent with the rising concept that CK2 plays a 
general role as anti-apoptotic agent [4]. On the other side, 
blocking its expression is associated with the induction of 
apoptosis of both in vivo and in vitro [5]. Thus, CK2 could 
be considered a hallmark of tumor progression. CK2 is 
frequently overexpressed in various types of human can-
cer, including lung cancer [6], and its overexpression can 
cause mammary tumors [7] and lymphomas [8].
It has been recently proposed that CK2-mediated phos-
phorylation could function as a druggable target to treat 
cancer [9]. Different groups have tried to manipulate CK2 
biochemical properties by targeting the ATP-binding site, 
the catalytic (α or α′) or regulatory subunits (β) of the 
holoenzyme (α α′/β β) or gene expression using antisense 
oligonucleotides [10, 11]. In this work we used the CIGB-
300, a synthetic peptide developed following an innova-
tive approach in order to target the phosphoaceptor site 
on the CK2 substrates rather than the enzyme per se, 
unlike most CK2 inhibitors [12].
Lung cancer is the most frequently diagnosed cancer 
and the leading cause of cancer-related deaths world-
wide [13]. Up to 80–85% of lung cancers are classified as 
non-small-cell lung cancer (NSCLC). Surgical resection 
is the most potentially curative therapeutic modality for 
this disease. Cisplatin-based neoadjuvant (cisdiammine-
dichloro-platinum) and/or adjuvant chemotherapy may 
provide an additional benefit to Stage II–IIIA patients and 
chemotherapy has produced short-term improvement in 
patients with advanced NSCLC [14, 15]. However innate 
and acquired resistance to cisplatin has become a major 
challenge in the management of lung cancer patients, 
indicating that it is imperative the development of new 
drugs with different mechanisms of action.
The lack of therapeutic alternatives, together with the 
knowledge that NSCLC overexpress CK2, make lung 
malignancies strong candidates for CIGB-300 treatment.
CIGB-300 is a proapoptotic peptide with established 
antiproliferative activity in  vitro affecting transformed 
cells of different origin [16] including NSCLC. However, 
the subsequent events that lead tumor cells death remain 
far to be fully elucidated.
Studies in Drosophila have implicated CK2 in the Wnt 
pathway involved in embryonic development. In addi-
tion, Wnt pathway is increasingly recognized to play 
a role in cancer development, through modulation of 
genes encoding β-CATENIN itself or its regulators. In 
the absence of Wnt ligands, the β-CATENIN is phospho-
rylated at its N-terminus region by a protein complex, 
inducing its destruction by the proteasome [17]. CK2 is 
able to phosphorylate several proteins of this destruction 
complex favoring its disruption, consequently increasing 
the levels of free β-CATENIN in the cytoplasm. Further-
more, CK2 is able to phosphorylate β-CATENIN Thr393 
increasing its stability [18]. Altogether these two pro-
cesses favor the increased levels of β-CATENIN in the 
nucleus where it acts as a transcription factor, favoring 
the expression of several proteins involved in cell prolif-
eration and apoptosis resistance [19].
NF-κB activation is a common event in cancer due to 
its antiapoptotic activity and pro-proliferative functions 
[20]. NF-κB is a dimeric transcription factor formed by 
p50, p52, p65/relA, relB, and c-rel subunits. Functional 
activation of NF-κB requires the separation from its 
inhibitor (IκB) in order to translocate to the nucleus and 
activate the transcription of target genes [21]. The loss of 
IκB occurs through a multistep process which includes 
phosphorylation signals, ubiquitination and finally pro-
teasomal degradation. Several kinases can start this deg-
radation cascade, including CK2 [22]. Classical NF-κB 
activators induce N-terminal phosphorylation, while 
CK2 induces an alternative C-terminal phosphorylation 
on Ser529, considered as a non-classic activation, also 
related to IκB degradation [23]. Moreover, CK2 also acts 
at multiple levels in NF-κB activation, as it targets not 
only IκB, but also other upstream IκB kinases [24] and 
p65 itself [25, 26].
As mentioned above, cisplatin response is not durable 
and lead to resistance, remaining as the main challenge in 
the treatment of NSCLC. Activation of NF-κB has been 
reported to be associated to cisplatin-induced cell resist-
ance among other specific molecules [27]. In fact, the 
interaction between CK2 and chemoresistance has never 
been analyzed before.
A common denominator of the above mentioned sign-
aling pathways is the proteolytic degradation mediated by 
the proteasome. 26S proteasome results from the associ-
ation between the 19S regulatory particle to the 20S core 
which presents proteolytic properties. This proteasome 
conformation plays a major role in protein degradation 
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by both ubiquitin-dependent and ubiquitin-independent 
mechanisms. CK2 is known to co-purify with 20S protea-
some preparations [28] and it has been also described as 
responsible for its phosphorylation mapped in the resi-
dues Ser-243 and Ser-250 close to the C-terminus [29]. 
On NF-κB signaling pathway proteasome is responsible 
not only for IκB degradation, but also is essential for the 
attenuation of p65 nuclear levels [30].
Among the many roles displayed by CK2, modulation 
of above mentioned pathways could be critical for the 
control of tumor development and dissemination. Intrin-
sic CIGB-300 features make this synthetic peptide not 
only a powerful tool for dissecting the biological func-
tions of CK2, but also an important anti-cancer drug. In 
this paper we demonstrate that CIGB-300 induces a sig-
nificant anti-proliferative response both in two- and in 
three-dimensional lung cancer cellular models by affect-
ing key signaling pathways associated with malignant 
progression. Moreover, this peptide showed improved 
effectiveness in a chemoresistance model associated with 
NF-κB inhibition. Altogether this new evidence indicates 
that CIGB-300 may become a new strategy for the treat-
ment of lung cancer patients.
Methods
Peptide synthesis
CIGB-300 and CIGB-300-biotin-conjugated were syn-
thesized as previously described by Perea et  al. [12]. 
Briefly, the peptides were synthesized on solid phase and 
purified by reverse-phase high-performance liquid chro-
matography. The catalytic peptide sequence was fused to 
the TAT fragment of the HIV-1 virus, which confers the 
compound the ability to pass through the cell membrane 
[31, 32]. Purity was verified by mass spectrometry.
Reagents and antibodies
Medium for cell culture was obtained from Life Tech-
nologies Inc. (Rockville, MD,USA). Fetal bovine serum 
(FBS) was from Internegocios (Buenos Aires, Argentina). 
Acrylamide and all other reagents for polyacrylamide gel 
electrophoresis were obtained from Bio-Rad (Richmond, 
CA, USA). Phorbol 12-myristate 13-acetate (PMA) and 
4,5,6,7-Tetrabromo-2-azabenzimidazole (TBB) were 
purchased from Sigma-Aldrich Co (St. Louis, MO, 
USA). Recombinant human tumor necrosis factor-alpha 
(TNFα) was purchased from ImmunoTools (Friesoythe, 
Germany). Bortezomib  (VELCADE®) was purchased 
from Millennium Pharmaceuticals (Cambridge, MA, 
USA) and cisplatin  (MARTIAN®) was purchased from 
Kampel Laboratory (Buenos Aires, Argentina). Anti-
NF-κB p65 (D14E12  XP®, 1:1000) was purchased from 
Cell Signaling (Danvers, MA, USA), β-CATENIN anti-
body (#610,153, 1:1.000) was from BD Transduction 
Laboratories (San Jose, CA, USA), Horseradish peroxi-
dase-conjugated anti-mouse (1:5000), Mouse monoclo-
nal anti c-MYC (sc-40, 1:100) and Mouse monoclonal 
anti CYCLIN E (sc-247, 1:200) were from Santa Cruz 
Biotechnology (Dallas, TX, USA). Anti-rabbit (1:5000) 
and β-ACTIN antibody (1:10.000) were from Sigma-
Aldrich Co. Monoclonal anti PSMA3 (α7/C8) antibody 
(ab109532, 1:100), Rabbit Monoclonal anti NF-κB p65 
(phospho S529) (ab109458, 1:1000) and Rabbit polyclonal 
anti BAX (ab69643, 1:1000) were from Abcam (Cam-
bridge, MA, USA), Streptavidin-FITC (SNN1008, 1:300) 
and CYCLIN D1 antibody (RB-9041, 1:10000) were from 
Invitrogen-Thermo Fisher (Waltham, MA), Goat Anti-
Rabbit IgG H&L Alexa  Fluor® 647 (ab150113, 1:250) and 
Goat Anti-Rabbit IgG H&L Alexa  Fluor® 488 (ab150079, 
1:1000) from Abcam. Hybond-P membranes for blot-
ting and chemiluminescence reagents (ECL) were from 
Amersham-GE Healthcare (Buckinghamshire, UK).
Cell lines and culture conditions
We used two human non-small cell lung cancer (NSCLC) 
derived cell lines: the adenosquamous cell carcinoma 
NCI-H125 (CRL-5801) and the adenocarcinoma NIH-
A549 (CCL-185). The murine L Wnt-3A cell line (CRL-
2647) was used in order to produce conditioned media 
(CM) containing the wnt3a factor, following ATCC’s 
instructions. All cell lines were obtained from ATCC. 
H125 was grown in RPMI medium supplemented with 
10% FBS and 80 µg/ml gentamycin. A549 and L cells were 
grown in DMEM media, with the above mentioned sup-
plementation. All cell lines were cultured at 37  °C in a 
humidified air atmosphere with 5%  CO2.
Treatments
For Wnt/β-CATENIN pathway studies, H125 sub-con-
fluent monolayers were first incubated during 24 h with 
50% of CM containing the wnt3a factor and then treated 
for another 6 h with a low-lethal dose of CIGB-300  (IC25) 
or during 2  h with the CK2 competitive inhibitor TBB 
(25 μM) as a control. For NF-κB studies, the H125, A549 
or A549-cispR cells were incubated for 15 or 45  min 
respectively with a low-lethal dose CIGB-300  (IC25) with 
or without PMA (16 nM), TNFα (10 ng/ml) or the  IC50 of 
cisplatin (1.0 µM for H125 and 5.0 µM for A549). For the 
analysis of NF-κB downstream targets, H125, A549 or 
A549-Rcisp cells were incubated for 2 h with CIGB-300 
 (IC50). In the case of Bortezomib, cells were previously 
pretreated with 8 nM of this drug during 4 h.
Cell viability and apoptosis determination
To assess the effect of CIGB-300 or cisplatin on cell via-
bility, 1 × 104 cells/well were seeded into 96 well plates 
in standard culture conditions. Twenty-four hours 
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later cells were treated with different doses of CIGB-
300 (25–400 μM) or cisplatin (0.3–30 μM) during 72 h. 
Cell proliferation was evaluated after 72  h using the 
MTS assay (Celltiter 96TM Non Radioactive Prolifera-
tion Assay, Promega), as described by the manufacturer. 
Data were analyzed using the R package “ic50” [33] in 
order to determine the  IC50 values for each drug. Alter-
natively, proliferative potential was determined by assess-
ing cell number. Briefly, cells were seeded onto 35  mm 
Petri dishes, treated and after 72  h wells were washed 
twice with PBS, trypsinized, centrifuged, resuspended 
in a proper volume and finally counted using an hemo-
cytometer and trypan blue exclusion. For apoptosis 
determination, A549 and A549-cispR cells growing on 
glass coverslips were treated with 300  μM of CIGB-300 
for 18  h and then stained with Acridine orange (10  μg/
ml) and Ethidium bromide (10 μg/ml). Visualization was 
performed with a Nikon, Eclipse E400 epifluorescence 
microscope. Uniform green nuclei with organized struc-
ture were considered as live cells. Bright green or orange 
to red nuclei were classified as early or late apoptotic cells 
respectively. Uniformly orange to red nuclei with organ-
ized structure were ascribed as necrotic cells. The per-
centage of dead cells was determined for each cell line.
3D cultures and peptide internalization assay
Multicellular tumor spheroids were obtained through the 
hanging-drop method [34]. Growth kinetic was evalu-
ated using spheroids formed from 1000 initial cells. For 
the 3D growth inhibition assay, each “drop” containing 
a single spheroid was placed in 500  μl of culture media 
supplemented with FBS onto 48 well plates on day 3. 
Two days later spheroids were treated or not with differ-
ent doses of CIGB-300  (IC25 and  IC50 obtained for mon-
olayer cultures). Complete culture media, supplemented 
or not with CIGB-300 was replaced every 48  h. At the 
same time, images were taken using an optical light 
microscope. The area, circularity and roundness of sphe-
roids were measured using a custom macro for ImageJ, 
and finally the volume was calculated. For peptide inter-
nalization kinetics, 2-day-old spheroids were treated 
with the biotinylated variant of CIGB-300 for 5–60 min. 
Spheroids were fixed in formaldehyde (4% in PBS) for 
30 min and embedded in paraffin. Sections of 5 μM were 
obtained using microtome on polylysine-coated slides. 
Finally, immunocytochemistry was performed using a 
Streptavidin–biotin method with the VECTASTAIN Elite 
ABC KIT from Vector Laboratories (Burlingame, CA, 
USA) following manufacturer’s instructions. Sections 
were counter-stained with Mayer’s hematoxylin. Images 
were taken using a light microscope, at 400× magnifica-
tion. Immunoreactive staining was quantified transform-
ing each image into polar coordinates and using the color 
detection tool of the ImageJ plugin Immunohistochemis-
try Image Analysis Toolbox [35].
Separation of nuclear and cytoplasmic fractions
In order to determine β-CATENIN expression lev-
els, cytoplasmic proteins were extracted using saponin 
buffer. Briefly, monolayer cultures were incubated for 
20  min with ice-cold 0.1% saponin lysis buffer (25  mM 
Hepes, 75 mM potassium acetate and 0.1% saponin plus 
phosphatase and protease inhibitors). The extraction 
procedure was carried out twice and the extracts were 
pooled prior to their centrifugation. For NF-κB detec-
tion, nuclear and cytoplasmic proteins were separated 
by differential centrifugation following Abcam protocol. 
Briefly, semiconfluent monolayers were washed twice 
with ice-cold PBS and then collected in 250  μl of Frac-
tionation Buffer (HEPES 20  mM, KCl 10  mM,  MgCl2 
2  mM, EDTA 1  mM and 2-Mercaptoethanol 1  M) with 
protease and phosphatase inhibitors by scrapping with a 
Teflon scrapper. Cell suspensions were passed 10 times 
through a 25 gauge needle, and leaved on ice for 20 min. 
Then samples were centrifuged at 700g for 5  min. The 
pellets, which contain nuclei, were washed repeating all 
the procedure, and finally resuspended in Nuclear Buffer 
(Fractionation Buffer plus 10% glycerol and 0.1% SDS). 
Supernatants were centrifuged again at 10,000g for 5 min 
and the supernatant, containing the cytoplasm and mem-
brane, was collected.
Western blot analysis
Semiconfluent monolayers were washed twice with ice-
cold PBS and then lysed with RIPA buffer (150 mM NaCl, 
1% NP-40, 50 mM Tris–HCl pH 8.0, 1 mM EDTA, 0.5% 
deoxycholate) with protease and phosphatase inhibitors 
by scrapping with a Teflon scrapper. Samples were run in 
10% SDS-PAGE, and the gels blotted to Hybond-P mem-
branes. Membranes were blocked for 1 h in 5% skim milk 
in TBS, 0.1% Tween-20. Membranes were then incubated 
with the first antibody overnight at 4 °C, and with a sec-
ondary antibody coupled to horseradish peroxidase [1 h 
at room temperature (RT)]. Detection was performed 
by chemiluminescence. Bands were digitalized with a 
Photo/Analyst Express System (Fotodyne Inc. Hartland, 
WI, USA) and signal intensity was quantified with ImageJ 
software.
NF‑κB‑dependent reporter gene expression
H125 cells were transiently co-transfected with NF-κB-
RE-luc Luciferase Reporter Vector pGL4.32 and the 
Renilla Luciferase Control Reporter Vector pRL-TK (Pro-
mega, Madison, WI) in a 10:1 ratio, using Fugene (Pro-
mega) following manufacturer’s instructions. Briefly, 
1  ×  105 cells/well were seeded onto 24-well plates and 
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transfected the next day. Six hours after adding transfec-
tion reagents, cells were washed and complete media was 
added. After an overnight recovery, cells were treated for 
6 h with PMA (16 nM), in presence or not of CIGB-300 
 (IC25) during the first hour. Finally cells were lysed and 
the luciferase activities were determined using the Dual-
Luciferase Reporter Assay System (Promega) and nor-
malized to the constitutive Renilla luciferase activity.
Immunofluorescence microscopy
H125 cells growing on glass coverslips were treated with 
CIGB-300 for 15 min in presence or not of PMA, washed 
twice with PBS, fixed in ice cold paraformaldehyde, per-
meabilized and blocked with PBS containing 5% bovine 
serum albumin for 1 h at RT. p65 protein was detected by 
incubation with a specific primary antibody diluted in PBS 
containing 5% BSA, followed by an incubation with a sec-
ondary antibody coupled to Alexa 488 for 1 h at RT. Nuclei 
were counterstained with DAPI. Images were obtained 
using an epifluorescence microscope (Nikon, Eclipse 
TE2000), processed and analyzed using the ImageJ soft-
ware. Nuclear intensity was measured taking into account 
the overlapping with DAPI staining. The number of nuclei 
with highly positive signal was counted and expressed as a 
percentage of the total intensity for each condition.
Generation of a cisplatin resistant cell line
Cisplatin resistant A549 lung cancer cell line (A549-
cispR) was obtained by the chronic administration of 
cisplatin  IC50 (5.0  μM) during 6  months as previously 
described [36]. Parental A549 cells were maintained in 
culture during the same period.
Drugs interaction analysis
To determine the combination index (CI) of CIGB-300 
and cisplatin, A549 and A549-cispR cells were treated 
with both drugs following a constant-ratio analysis. 
Briefly, drug mixture was serially diluted and added for 
72 h to cells seeded onto a 96 well plate. Drugs and media 
were refreshed every 24  h. The combination ratio used 
was approximately equal to the  IC50 ratio for each drug. 
Three points below and above the  IC50 value were used 
for each mixture. Effects of all the mixture points were 
displayed using the form CI vs. Fa, where Fa is fraction 
affected and represents the respective proliferation inhi-
bition parameters (e.g., a Fa of 0.5 is a proliferation inhi-
bition of 50%). CI plot values were obtained from three 
different experiments using the Compusyn software [37].
Proteasome activity determination
Proteasome activity was assessed in H125 cells using the 
Proteasome-Glo Chymotrypsin-Like Cell-Based Assay 
(Promega) following manufacturer’s instructions. Briefly, 
H125 cells were plated onto 96-well plates and 24  h later 
treated with CIGB-300 (30 min) or with Bortezomib (4 h). 
Briefly: 100  µl of Proteasome-Glo™ Cell-Based Reagent 
were added to each 100 µl of sample and incubated at RT for 
10 min. Luminescence emission was measured with a Mul-
timode Microplate Reader, Synergy luminometer (Biotek).
Confocal immunofluorescence
H125 cells growing on glass coverslips were treated with 
biotin-conjugated CIGB-300 for 30  min, washed twice 
with PBS, fixed in ice cold paraformaldehyde, permeabi-
lized and blocked with PBS containing 5% bovine serum 
albumin for 1  h at RT. α7/C8 protein was detected by 
incubation with a specific primary antibody diluted in 
PBS containing 5% BSA, followed by an incubation with 
a secondary antibody coupled to Alexa 647 and with 
Streptavidin-FITC conjugated for 1 h at RT. Nuclei were 
stained with DAPI. Images were obtained in a LSM 510 
Meta confocal Zeiss microscope. Confocal images were 
processed for presentation with ImageJ. Background of 
each channel was subtracted. Pearson’s and Mander’s 
coefficients were calculated using the JACoP plugin [38]. 
Single cell analysis for 15–20 representative cells was per-
formed on three independent experiments.
Statistical analysis
Data obtained were evaluated for their statistical signifi-
cance with the two-tail paired Student’s t test or analysis 
of variance (ANOVA) with post hoc corrections. Values 
were considered statistically significant at p below 0.05.
Results
CIGB‑300 is able to penetrate into lung cancer 
three‑dimensional spheroid cultures inhibiting their 
growth at the same effective dose than in monolayer 
cultures
Previous reports describe the antiproliferative and pro-
apoptotic effects of CIGB-300 on several cancer cell lines 
[39, 40]. In order to confirm the effect of CIGB-300 on 
NSCLC, H125 and A549 monolayers were treated with 
different doses of the peptide. Both cell lines responded 
to CIGB-300 with  IC50 values of 124.2 μM and 271.0 μM 
(H125 and A549, respectively), H125 being the most sus-
ceptible and our first model choice for further mechanis-
tic studies (Fig. 1a). Given multicellular tumor spheroids 
are a good in vitro model for drug delivery to early-stage 
avascular tumors as well as micrometastases, CIGB-300 
effectiveness was also evaluated on three dimensional cul-
tures. We tested CIGB-300 on H125 spheroids using the 
 IC25 and  IC50 doses previously determined for monolay-
ers. After 5 days of treatment, the volume of CIGB-300-
treated spheroids was significantly lower for both assessed 
doses compared with untreated controls. Moreover, on 
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day 7, the volume of treated spheroids dropped markedly, 
even reaching initial volume values for  IC50 treated sphe-
roids (Fig. 1b). Thus, the peptide proved to be effective for 
both two- and three- dimensional cultures at equivalent 
doses. We hypothesized this could be related with CIGB-
300 ability to penetrate into the spheroid compact struc-
ture, where most of the chemotherapeutic agent fail to 
accomplish a fast and effective entrance [41–44]. There-
fore, H125 spheroids were treated with a biotinylated ver-
sion of the peptide and tracked over time. Interestingly, a 
moving front was detected as soon as 5 min after initiation 
of the treatment and complete penetration into the sphe-
roid core was observed at 60 min (Fig. 1c). Based on these 
results, a low-lethal  (IC25: 60  μM for H125 and 150  μM 
for A549) and a high-lethal  (IC50: 120 μM for H125 and 
300 μM for A549) CIGB-300 doses were selected for use 
in the following experiments.
CK2‑dependent signaling pathways are affected 
by CIGB‑300 treatment
Since CK2 has more than 300 intracellular substrates 
[45], several signaling pathways might be potentially 
altered by CIGB-300 [1]. In the present work we studied 
two of the more relevant due to their role on survival and 
apoptosis inhibition [46]: the canonical NF-κB and Wnt/
β-CATENIN pathways.
The canonical NF-κB pathway activation requires phos-
phorylation by CK2 to allow the nuclear translocation of 
the NF-κB complex. As shown in Fig. 2a, low-lethal dose 
of CIGB-300 reduced the nuclear levels of the p65/relA 
NF-κB complex subunit in H125 cells, while cytoplasmic 
p65 levels accumulated. This inhibitory effect was sus-
tained even after the addition of PMA, an NF-κB activa-
tor. Consistently, the phosphorylation of the CK2 specific 
site in p65 induced by TNFα was reduced in the presence 
of CIGB-300 (Fig. 2a bottom, lane 2 vs. lane 4). In order to 
determine the extent of NF-κB inhibition after CIGB-300 
treatment, the expression of several NF-κB downstream 
targets, such as CYCLIN D1, CYCLIN E and BAX, was 
evaluated by Western blot. As shown in Fig. 2b, both cyc-
lins were downregulated whereas the proapototic protein 
BAX was upregulated. Moreover, we observed decreased 
NF-κB transcriptional response upon CIGB-300 treat-
ment in the presence of PMA using a reporter gene assay 
(Fig. 2c). Finally, in line with the above described results, 
we could visualized by immunofluorescence the reduced 
p65 nuclear intensity after CIGB-300 treatment (Fig. 2d). 
PMA treated cells presented highly positive nuclei that 
were reduced upon combination with CIGB-300 (Fig. 2d, 
white arrows and representative insets). Taken together, 
all these evidences confirm the inhibition of NF-κB path-
way by CIGB-300.
(See figure on previous page.) 
Fig. 1 Anti-proliferative effect of CIGB-300 on 2D and 3D cultures. a  IC50 determination for H125 monolayer cultures. Each value represents the 
mean ± SD of three independent experiments. b The  IC50 dose obtained in H125 cells growing in monolayer was tested on multicelullar tumor 
spheroids. Each value represents the mean ± SD of three independent experiments. *p < 0.001 vs. H125 spheroids without treatment, 2-way 
ANOVA test (left side). Representative images for three different experiments were taken after 5 days of treatment, scale bar 100 μM (right side). c 
Internalization studies on H125 spheroids were performed treating cells from 5 to 60 min with a biotin-labeled CIGB-300 and visualized by immuno-
cytochemistry. Representative images of three different experiments. Zoom 400×, scale bar 100 μm (top). Immunoreactive staining was quantified 
as a function of the distance to the spheroid center for each condition (bottom)
(See figure on next page.) 
Fig. 2 Effect of CIGB-300 on CK2-dependent signaling pathways. a Nuclear, cytoplasmic or whole cell extracts prepared from H125 cells treated 
with low-lethal doses of CIGB-300 in combination or not with an activating stimulus, were resolved on 10% SDS-PAGE and blotted with p65/RelA 
and P-p65 (Ser529) antibodies (50 μg protein/lane). ACTIN expression level was used as protein loading control. For the determination of p65 levels 
PMA was used as the activating stimulus, while TNFα was used for P-p65 determinations. Results are representative of three independent experi-
ments. b Whole cell extracts prepared from H125 cells treated with CIGB-300, were resolved on 10% SDS-PAGE and blotted with CYCLIN D1, CYCLIN 
E and BAX antibodies (50 μg protein/lane). ACTIN expression level was used as protein loading control. c H125 cells were transiently co-transfected 
with pNF-κB-RE-luc and pRL-TK-luc vectors, treated with low-lethal doses of CIGB-300 in combination or not with PMA and luciferase activity was 
determined. Data were normalized to the constitutive Renilla luciferase activity and expressed as the mean ± SD. **p < 0.01 vs. PMA treated cells 
and *p < 0.05 PMA + CIGB-300 treated cells vs. PMA treated cells (one-way ANOVA test). Results are representative of three independent experi-
ments. d H125 cells were treated with low-lethal doses of CIGB-300 in combination or not with PMA. Cellular distribution of p65 was visualized by 
immunofluorescence microscopy. Figure shows representative images of three independent experiments, scale bar 50 μm. White arrows indicate 
highly positive nucleus. Representative insets of cells treated with PMA in combination or not with CIGB-300 are shown, scale bar 5 μm (left side). 
Relative p65 nuclear intensity was measured and represented as a percentage of control cells (light gray bars). **p < 0.01 vs. CIGB-300 treated cells 
(one-way ANOVA test). The percentage of those cells with highly positive nucleus (white arrows) was also measured (dark gray bars). **p < 0.01 vs. 
PMA treated cells and *p < 0.05 PMA + CIGB-300 treated cells vs. PMA treated cells (one-way ANOVA test) (right side). e H125 cells were incubated 
with CM containing the wnt3a factor and then treated with low-lethal doses of CIGB-300 or TBB. Cytoplasmic protein content was separated by 
SDS-PAGE 10% and the membrane was blotted with anti β-CATENIN antibody (50 μg protein/lane). ACTIN expression level was used as protein 
loading control. Results are representative of three independent experiments
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In the Wnt/β-CATENIN pathway, CK2 phosphoryl-
ates and stabilizes β-CATENIN allowing transloca-
tion to the nucleus and transcription of target genes 
[18]. Basal levels of cytoplasmic β-CATENIN were not 
reduced after CIGB-300 treatment. However, when the 
Wnt/β-CATENIN pathway was active, in response to the 
treatment with a CM containing soluble wnt3a factor, 
CIGB-300 partially reverted β-CATENIN cytoplasmic 
accumulation, suggesting the involvement of the peptide 
on the blockade of β-CATENIN signaling (Fig. 2b). Addi-
tionally, the competitive CK2 inhibitor TBB [47] pro-
duced similar effects on β-CATENIN accumulation than 
CIGB-300.
Cisplatin‑resistance is associated with NF‑κB signaling 
on NSCLC cells
It is known that cancer patients’ refractoriness to cispl-
atin-based chemotherapy may be associated with NF-κB 
signaling activation [48–50]. Since CIGB-300 prevented 
NF-κB nuclear translocation even in the presence of an 
activating stimulus, we explored in vitro whether its com-
bination with cisplatin could generate some therapeutic 
benefit. In fact, H125 cells treated with cisplatin showed 
an important increase in nuclear p65 levels, which were 
comparable or even stronger than those displayed by the 
same cell line under PMA stimulus (Fig.  3a). Moreover, 
CIGB-300 was able to impair the increased p65 levels 
observed under the chemotherapeutic treatment (Fig. 3a, 
lane 5). These results prompted us to evaluate CIGB-300 
effectiveness in a chemoresistant setting. To this end, we 
developed a cisplatin resistant variant of the NSCLC cell 
line A549. Chronic supplementation with the  IC50 dose 
for cisplatin during 6  months allowed us to obtain the 
A549-cispR variant. As shown in Fig.  3b, after cisplatin 
treatment, the viability of the new resistant cell line was 
twofold higher than that in the parental cells, and these 
differences were sustained over time and even after two 
cycles of thawing/freezing, confirming cisplatin-acquired 
resistance. Surprisingly, A549-cispR expressed lower 
total p65 levels than A549 (Fig. 3c). Nevertheless, when 
both cell lines were treated with cisplatin they showed 
different NF-κB activation patterns. While parental cells 
decreased p65 nuclear levels after treatment, the cispl-
atin-resistant cell line showed higher levels (Fig. 3d).
Cisplatin‑acquired‑resistance sensitizes to CIGB‑300 
treatment
Based on the previous evidence that cisplatin resistance 
acquisition was accompanied with NF-κB activation, 
and given that CIGB-300 blocked the cisplatin response, 
we evaluated the effect of the combination treatment 
on both resistant and parental A549 cell lines. When 
we combined low-lethal CIGB-300 dose with cisplatin 
we could observe a higher but non-significant response 
than with the single treatments (Fig.  4a). To determine 
the kind of interaction between these drugs, we calcu-
lated the combination index (CI) using Chou and Tala-
lay method [37]. Neither parental nor resistant cell lines 
present an agonist or synergistic interaction along all the 
fraction affected values analyzed (CI > 1) (Fig. 4b). Nev-
ertheless, a higher response to CIGB-300 was observed in 
the cisplatin resistant A549 cell line when we used higher 
CIGB-300 doses (Fig. 4c). The sensitization to CIGB-300 
was also corroborated by a significant  IC50 reduction 
(A549: 271 ± 16 μM vs. A549-cispR: 249 ± 15 μM; T test 
p  <  0.01) and apoptosis assessment by acridine orange/
ethidium bromide double staining, where the number 
of dead cells on A549-cispR was significantly increased, 
presenting in both cell lines early and late apoptosis, as 
well as necrosis in a minor proportion (Fig. 4d). In order 
to explore the molecular mechanisms involved in the 
response of both cell lines to CIGB-300, we analyzed 
the modulation of nuclear p65 levels as well as NF-κB 
downstream targets. In both parental and resistant A549 
variants, the treatment with CIGB-300 reduced the p65 
nuclear levels, even in presence of cisplatin (Fig.  4e). 
Regarding downstream targets, the proapoptotic pro-
tein BAX levels increased in both cell lines after CIGB-
300 treatment. Interestingly, c-MYC protein, which is 
involved in proliferation, was distinctively inhibited only 
on the A549-cispR cell line (Fig. 4f ).
NF‑κB is modulated through enhanced proteasome 
activity
To investigate how CIGB-300 inhibits NF-κB, we stud-
ied some of the main molecular mechanisms involved in 
the downregulation of p65 nuclear levels. Neither the IκB 
inhibitor nor the basal phosphorylation on CK2-specific 
p65 site were affected after CIGB-300 treatment, indicat-
ing that other processes are involved (data not shown). 
We could determine that the inhibition of p65 nuclear 
translocation, induced by CIGB-300, was prevented by a 
pretreatment with the proteasome inhibitor Bortezomib 
(Fig. 5a, lane 4), thus indicating that proteasome activity 
is necessary for the effect observed on NF-κB modula-
tion. Indeed, we found that CIGB-300 increased protea-
somal activity in H125 cells under the same conditions 
than inhibit nuclear p65 levels (Fig. 5b). Then we inves-
tigated which proteasomal proteins could be involved. 
We focused in α7/C8, a member of the proteasome 
alpha-ring, since previous evidence showed that this CK2 
substrate co-precipitated with CIGB-300 in a pull-down 
assay (Perea and collaborators, unpublished data). Hence, 
we explored CIGB-300 and α7/C8 cell distribution by 
immunofluorescence. The protein α7/C8 was localized 
only in cytoplasm. In contrast, CIGB-300 was found both 





Fig. 3 NF-κB signaling pathway status after cisplatin treatment. a H125 cells were treated with low-lethal doses CIGB-300 for 45 min in the pres-
ence or not of cisplatin. Nuclear extracts were prepared, resolved in 10% SDS-PAGE and blotted with anti p65/RelA antibodies (50 μg protein/lane). 
ACTIN expression level was used as protein loading control. Results are representative of three independent experiments. b A549 and A549-cispR 
cultures were treated with cisplatin and cell number was assessed 72 h later. Viability values were compared to those obtained in both cell lines 
without treatment, which were set as 100%. Data expressed as the mean ± SE are representative of three independent experiments. *p < 0.05 vs. 
the parental cell line (Student’s t test). c Whole cell lysates prepared from A549and A549-cispR cells were resolved on 10% SDS-PAGE and blotted 
with anti p65/RelA antibodies (50 μg protein/lane). ACTIN expression level was used as protein loading control. Results are representative of three 
independent experiments. d Nuclear extracts prepared from A549and A549-cispR cells treated with cisplatin were resolved on 10% SDS-PAGE and 
blotted with anti P65/RelA antibodies (50 μg protein/lane). ACTIN expression level was used as protein loading control. Results are representative of 
three independent experiments




Fig. 4 Evaluation of Cisplatin and CIGB-300 combined treatment in a chemo-resistant setting. a A549 and A549-cispR cells were treated with low-lethal 
doses of CIGB-300 (150 μM) and/or Cisplatin and cell number was assessed 72 h later. Viability values were compared to those obtained in both cell 
lines without treatment, which were set as 100%. Data represent the mean ± SE of three independent experiments. *p < 0.05 vs. the parental cell line 
(one-way ANOVA test). b Chou and Talalay combination index (CI) plot for CIGB-300 and Cisplatin values of three independent experiments. c A549 and 
A549-cispR cells were treated with a high dose of CIGB-300 (300 μM) during 72 h and cell viability was evaluated using the MTS assay. Viability values 
were compared to those obtained in both cell lines without treatment, which were set as 100%. Data represent the mean ± SE of three independent 
experiments. *p < 0.01 vs. the parental cell line (Student’s t test). d A549 and A549-cispR cells were treated with a high dose of CIGB-300 (300 μM) dur-
ing 18 h and apoptosis induction was visualized by an acridine orange/ethidium bromide double staining assay. Figure shows representative images 
of three independent experiments (left side). The number of dead cells was quantified and expressed as a percentage of the total cell number for each 
cell line (right side). Data represent the mean ± SE of three independent experiments. *p < 0.05 vs. the parental cell line (Student’s t test). e A549 and 
A549-cispR cells were treated with 150 μM of CIGB-300 for 90 min in the presence or not of cisplatin. PMA was used as control. Nuclear extracts were 
prepared, resolved in 10% SDS-PAGE and blotted with anti p65/RelA antibodies (50 μg protein/lane). ACTIN expression level was used as protein load-
ing control. Results are representative of three independent experiments. f Whole cell extracts prepared from A549 and A549-cispR cells treated with 
300 μM of CIGB-300, were resolved on 10% SDS-PAGE and blotted with BAX and c-MYC antibodies (50 μg protein/lane). ACTIN expression level was 
used as protein loading control
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c
Fig. 5 Association between NF-κB modulation and proteasome activity. a H125 cells pretreated with a non-cytotoxic dose of Bortezomib were 
exposed to CIGB-300. Nuclear extracts were prepared, resolved in 10% SDS-PAGE and blotted with anti p65/RelA antibodies (50 μg protein/lane). ACTIN 
expression level was used as protein loading control. Results are representative of three independent experiments. b Proteasome activity determina-
tion following the Proteasome-Glo™ cell-based assay for H125 treated with CIGB-300 or Bortezomib (Bz) as positive control. Data was expressed as the 
mean ± SE of three independent experiments. *p < 0.05 vs. Bz treated cells and ***p < 0.001 vs. control treated cells (one-way ANOVA test). c Cellular 
distribution of CIGB-300 (green, FITC) and α7/C8 protein (red, Alexa647) was visualized by confocal microscopy (top). Figure shows representative images 
of three independent experiments. Single cell analysis of Pearson and Manders coefficients were performed, as well as a representative colocalization 
map and a dot plot for both probes (bottom). Coefficient values are expressed as the mean ± SE of three independent experiments
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in the nuclear and cytoplasmic compartments. While 
one-third of the cells presented strong mark of CIGB-
300 in the nucleus, the rest showed cytoplasmic signal, 
mainly located in the perinuclear area. Remarkably, in 
the latter group of cells, high CIGB-300 co-occurrence 
with α7/C8 was evidenced. More than 80% of α7/C8 is 
coincident with CIGB-300 presence (Fig. 5c), confirming 
the association between CIGB-300 and the CK2 protea-
somal substrate α7/C8.
Discussion
In this paper, we demonstrate that CIGB-300 induces a 
significant anti-proliferative effect on 2D and 3D NSCLC 
cultures. Both cell lines studied exhibited a response to 
CIGB-300. The differences in the  IC50 values between 
them may be linked to p53 status: while A549 is a p53 
wild-type cell line, H125 cells express a non-functional 
p53 variant. Drug-treated spheroids presented a lower 
growth rate from day 1 to 6 and suffered a great shrink-
age at day 7, which may be caused by the induction of cell 
death as a consequence of 5 days of treatment. Remark-
ably, CIGB-300 treatment on spheroids cultures resulted 
effective using the same doses for monolayer cultures 
treatments. Most cancer drugs show less growth inhi-
bition when cells are grown as multicellular aggregates 
[51, 52]. Several factors are responsible for this differ-
ence, including drug penetration capacity and survival-
signaling activation, prompted by cell–cell interactions 
such as PI3  K/Akt, NF-κB and Stat3 [53]. Doublier and 
col. have demonstrated that mammary tumor spheroids 
were less sensitive to doxorubicin and presented reduced 
drug uptake than monolayer cultures [54]. Furthermore, 
Fayad and col. found that cisplatin only affect the periph-
eral 30  μm cell layer of a three-dimensional carcinoma 
model, even in presence of high doses and after 96 h of 
treatment [55]. In this context, CIGB-300 proved to be 
effective both in 2D and 3D cultures and this is consist-
ent with the fact that internalization in 3D structures was 
rapid and complete, probably due to its peptidic nature 
and the presence of the cell-penetrating peptide TAT 
[31].
To our knowledge, this is the first work studying 
CIGB-300 effects on pathways linked to CK2 signal-
ing on lung cancer, thus extending previous findings 
on CIGB-300 mechanism of action [40]. In this regard, 
the canonical NF-κB pathway appeared as the most 
relevant, where nuclear RelA/p65 levels were severely 
and significantly reduced by CIGB-300 in all the ana-
lyzed lung cancer cell lines. Supporting this finding, 
the NF-κB downstream target and proaptotic protein 
BAX was increased after CIGB-300 treatment in the 
same cell lines, while the expression of other target pro-
teins such as cyclins (D1 and E) and c-MYC appeared 
downregulated on H125 and A549-cispR respectively. In 
addition, transcription of the NF-κB Response Element 
was conditionally affected by CIGB-300, as well as the 
number of positive p65 nuclei visualized by immuno-
fluorescence microscopy. However, we did not observe 
differences after CIGB-300 treatment on the transcrip-
tion levels of the NF-κB-RE-luc in the absence of PMA, 
indicating that a context of NF-κB stimulation might be 
necessary to detect the modulation on the transcription 
of the luciferase gene.
In line with our findings, recent reports have shown 
that the CK2 inhibitor CX-4945 impairs NF-κB pro-
moter activity in human head and neck squamous cell 
carcinoma lines [56] and reduces p65 phosphorylation on 
Ser529 (a CK2 target site) in multiple myeloma cells iso-
lated from patients [57]. These studies also highlight that 
p65 is one of the main targets of CK2 inhibitors. We also 
found that CIGB-300 altered the phosphorylation of p65 
on Ser529 caused by TNFα. This evidence reinforce our 
results and also suggest a direct implication of CIGB-300 
on the NF-κB signaling, but not explain the reduced p65 
nuclear levels caused by the treatment in the absence of 
TNFα, where proteasome-mediated degradation seems 
to be involved.
In addition, the relevance of NF-κB activation on lung 
cancer metastasis has been well documented [58, 59]. 
On this regard, our findings are in agreement with those 
presented by Benavent and col. who recently showed that 
CIGB-300 was capable of reducing tumor cell dissemi-
nation and colonization into the lung, thus displaying a 
powerful antimetastatic effect [60].
In contrast, neither the peptide nor the classical CK2 
inhibitor TBB affected the cytoplasmic basal levels of 
β-CATENIN, indicating that CIGB-300 anti-proliferative 
effect does not depend on the Wnt/β-CATENIN pathway 
under these conditions. Nevertheless, this may be due 
to the low basal β-CATENIN levels in these cells, which 
could be modulated only upon pathway activation with a 
Wnt ligand such as wnt3a factor. Therefore the CIGB-300 
effect on Wnt/β-CATENIN pathway might be relevant in 
tumor cells with high constitutive levels of β-CATENIN, 
due to constitutive or transient microenvironmental acti-
vation [61].
Proteasome degradation complex has become relevant 
in the last years as a promising druggable target follow-
ing the clinical success of Bortezomib [62]. Here we 
propose a new CIGB-300 target, the CK2 substrate and 
member of the proteasome proteolytic core 20S: the sub-
unit PSMA3 (originally named as α7/C8). This is based 
in our findings of CIGB-300 co-occurrence with α7/C8 
together with perturbed proteasome activity. Moreover, 
modulation of the proteasome machinery with analogous 
peptides has been described by Zanin and col [63]. The 
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fact that proteasome activation is necessary for nuclear 
p65 inhibition suggests an interesting link between both 
CIGB-300 effects and deserves further analysis.
It has been previously described that CIGB-300 co-
localizes in the nucleus with Nucleophosmin/B23 and 
inhibits its phosphorylation, abolishing ribosome bio-
genesis and rapidly resulting in apoptosis of a fraction 
of NSCLC cells [40]. The results presented in this paper 
extend the described mechanism of action and suggest 
that the inhibition of survival pathways may be responsi-
ble for long term anti-proliferative effects.
Refractory tumors to cisplatin therapy remain as one of 
the main challenges in the treatment of NSCLC patients. 
New second-line therapies are needed in order to improve 
the patient outcome. Here we generated an in vitro well-
characterized cisplatin resistance model which mimics the 
clinical setting of patients resistant to cisplatin-based ther-
apies [36]. The resistant cell line showed lower total levels 
of p65, but the pathway was highly inducible upon cispl-
atin exposure, in contrast with the parental A549 cell line 
that exhibited the opposite pattern. This result is consist-
ent with previous reports indicating that NF-κB nuclear 
translocation and DNA binding is induced after the treat-
ment with other chemotherapeutic agents in NSCLC cell 
lines [48]. Moreover, it has been also described that several 
NF-κB inhibitors lead to an increased therapeutic efficacy 
of cisplatin [50]. In our model, the activation of NF-κB 
after cisplatin treatment was a consequence of the chronic 
cisplatin exposure, and may be necessary for the acquisi-
tion of resistance. Although unexpected, the decrease in 
p65 total levels might result from a high turnover caused 
by chronic activation of the pathway due to the constant 
presence of cisplatin.
Remarkably, the cisplatin-resistant cell line resulted 
more sensitive to CIGB-300 than the parental one. 
Although CIGB-300 concentration is high, it has still 
clinical relevance, as can be inferred from previous in vivo 
assays where high doses (up to 40  mg/kg/day) admin-
istered intravenously were safe, well tolerated and non-
toxic, with biodistribution values up to 1.5% of peptide 
uptake at tumor site 24 h post intravenous injection [64].
The sensitization to CIGB-300 may be partially due to 
the acquired dependence to the NF-κB signaling pathway 
caused by the previous cisplatin exposure. Nevertheless, 
additional mechanisms may be contributing to resistance. 
In this sense, the downregulation of the NF-κB transcrip-
tional target c-MYC, which was distinctively diminished 
in A549-cispR cells after CIGB-300 treatment, may be 
involved in the mechanism underlying the increased sensi-
tivity to CIGB-300. Furthermore, recent reports have asso-
ciated c-MYC with the acquisition of cisplatin resistance 
on A549 cells, while its blockade increased apoptosis rate 
[65].
Therefore, CIGB-300 treatment may be considered for 
refractory patients after standard cisplatin-based chemo-
therapy in a sequential scheme of treatment. Neverthe-
less, more preclinical data are needed before addressing 
CIGB-300 as a second-line therapeutic approach after 
cisplatin in prospective trials.
Conclusions
We demonstrate that CIGB-300 induced an anti-prolifer-
ative response in NSCLC models. This effect was accom-
panied by the inhibition of the NF-κB pathway, which 
was associated with an enhanced proteasome activity. 
Moreover, the NF-κB pathway appeared to be critically 
involved in the cisplatin- resistance of A549-cispR cells, 
which became more sensitive to CIGB-300 treatment.
In conclusion, we have successfully demonstrated that 
CIGB-300 modulates several CK2-dependent signal-
ing pathways and may have a potential utility on current 
NSCLC therapy.
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